StockData
Silexion Therapeutics Corp logo

Silexion Therapeutics Corp (SLXN) income statement

SLXNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SLXNW
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$0.15+0.00 (0.00%)

Close on Oct 19, 2026Market cap $28.29KP/E 0.0Yield –

Silexion Therapeutics Corp income statement

Ratios

Latest available, balances at Sep 30, 2026

Profitability, FY

Gross margin
–
Operating margin
–
Net margin
–
Return on equity, FY2025
1718.9%

Financial strength

Current ratio
1.66
Debt to equity
–
Debt to assets
–
Cash to current liabilities
129.3%

Valuation

P/E ratio
0.0
Price to sales
–
Price to book
0.01
Dividend yield
–

See a number that looks wrong?